OLGA
MERINO OCHOA
Hospital Universitario de Basurto
Bilbao, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario de Basurto (19)
2023
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
2022
-
Corrigendum to: Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy
Inflammatory bowel diseases
-
Erratum: Re-induction with Intravenous Ustekinumab in Patients with Crohn's Disease and a Loss of Response to This Therapy (Inflammatory Bowel Diseases DOI: 10.1093/ibd/izab015)
Inflammatory Bowel Diseases
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
-
Re-induction With Intravenous Ustekinumab in Patients With Crohn's Disease and a Loss of Response to This Therapy
Inflammatory bowel diseases, Vol. 28, Núm. 1, pp. 41-47
2020
-
Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain)
Gastroenterology, Vol. 159, Núm. 2, pp. 781-783
-
Early microscopic findings in preclinical inflammatory bowel disease
Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1467-1472
-
Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry
Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616
2019
-
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500
-
Immunosuppression for inflammatory bowel disease does not influence Epstein–Barr viral load in the short-term
Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 542-547
2018
-
Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors
Digestive and Liver Disease, Vol. 50, Núm. 8, pp. 812-819
-
Characteristics and Progression of Preclinical Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1459-1466
-
Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry
American Journal of Gastroenterology, Vol. 113, Núm. 7, pp. 1009-1016
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131
-
Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study
American Journal of Gastroenterology, Vol. 112, Núm. 11, pp. 1709-1718
2016
-
Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease
Revista Espanola de Enfermedades Digestivas, Vol. 108, Núm. 9, pp. 550-557
2014
-
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293